Development of a Novel PET Tracer for Imaging Microglial Function in Alzheimer's Disease
开发一种新型 PET 示踪剂,用于对阿尔茨海默氏病的小胶质细胞功能进行成像
基本信息
- 批准号:10834001
- 负责人:
- 金额:$ 4.04万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-09 至 2024-09-08
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAdenosine DiphosphateAdultAlzheimer&aposs DiseaseAlzheimer&aposs disease brainAlzheimer&aposs disease patientAlzheimer&aposs disease riskAmyloid beta-ProteinAnti-Inflammatory AgentsAutopsyAutoradiographyBasic ScienceBindingBiochemical ProcessBiological MarkersBrainCNR2 geneCSF1R geneCarbonCause of DeathCellsCentral Nervous SystemChemotaxisChronicClinicalDataDementiaDevelopmentDiseaseDisease ProgressionDoctor of PhilosophyEarly DiagnosisEarly treatmentEffector CellEnvironmentEvaluationFellowshipFormulationFunctional ImagingFutureGenesGoalsHumanImageImmuneImmune systemIn VitroInflammationInflammatoryKnockout MiceLipopolysaccharidesMeasuresMedicineMentorsMentorshipMicrogliaModelingMolecularMonitorMorphologyMusMyeloid CellsNeuroimmunePathogenesisPathologyPhysiciansPlasmaPositron-Emission TomographyProcessProteinsRadiolabeledResearchResearch PersonnelResourcesRisk FactorsRodentRoleSaimiriSalineScientistSenile PlaquesSpecificityTimeTracerTrainingTransgenic MiceVisualizationWorkbrain cellbrain tissuecareercell typeclinical translationdrug candidateexperiencegenome wide association studyglial activationhuman diseasehuman modelhuman tissueimaging approachimaging modalityimaging studyimmune activationimmunomodulatory therapiesin vivoinnate immune functioninnovationmolecular imagingmouse modelneuroinflammationnonhuman primatenovelpharmacologicradiotracerreceptorresearch studyskillsspatiotemporalspecies differencespecific biomarkerstargeted treatmenttau Proteinstherapy developmenttooltranslational potentialuptake
项目摘要
SUMMARY
Alzheimer’s disease (AD) is the most common form of dementia and a major cause of death in adults over 65.
Unfortunately, advancements in early diagnosis and treatment development have been hindered by a paucity of
sensitive biomarkers enabling detection of early, functionally relevant, neuromolecular changes: Although data
from genome wide association studies have revealed genes relating to a loss of healthy innate immune function
as a major risk factor for AD, there remains a need for biomarkers to investigate neuro-immune function
preceding and during the development of this disease. Positron Emission Tomography (PET) is an extremely
sensitive molecular imaging modality well suited to studying such biomarkers, with established utility for non-
invasive in vivo interrogation of biochemical processes. Existing PET biomarkers of neuroinflammation (e.g., the
translocator protein 18 kDa [TSPO], CB2, CSF1R, P2X7) suffer from significant drawbacks including a poorly
elucidated functional role and/or expression across multiple cell types in the central nervous system (CNS).
Within the CNS, the adenosine diphosphate receptor P2Y12R is expressed exclusively on microglia, the innate
immune effector cells of the CNS, and drives chemotaxis and morphological changes associated with microglial
activation. Generally considered a biomarker of homeostatic microglia, P2Y12 expression has been
demonstrated to decrease in both acute (e.g., lipopolysaccharide challenge) and chronic (e.g., AD)
neuroinflammation. Postmortem human brain tissue from advanced AD patients demonstrated a global
reduction in P2Y12R expression and a near total absence of P2Y12R expression on microglia surrounding
amyloid-beta plaques. Despite being an extremely well characterized pharmacological target, there are currently
no CNS-penetrable P2Y12R PET tracers. Aiming to address this unmet need, I identified clinical drug candidate
AZD1283 as a promising possible PET tracer. Recently, I devised a strategy to radiolabel this molecule with
carbon-11 (t1/2=20.4 min), synthesized [11C]AZD1283 and showed it to be highly stable in vitro in human plasma.
Here, I will compare [11C]AZD1283 with TSPO PET tracer [11C]DPA-713 for their ability to measure alterations
in microglia in two murine models of neuroinflammation (Aim 1). Additionally, I will assess the translational
potential of [11C]AZD1283 through imaging healthy non-human primates and in vitro autoradiography of human
AD brain tissue (Aim 2). The experience gained by pursuing these aims will allow me to develop a skillset directly
applicable to future independent research developing tracers and therapies that target the immune system. I will
conduct this work under the mentorship of Michelle James, PhD, a world expert in neuroinflammation PET, with
additional mentorship from Thomas Montine, MD, PhD, the chair of Pathology at Stanford. Their mentorship, in
conjunction with the excellent training environment and resources available to me at Stanford, are highly
conducive to successful completion of this project, and will ultimately enable a successful transition to a career
as an innovate and effective independent physician scientist.
概括
阿尔茨海默氏病(AD)是痴呆症的最常见形式,也是65岁以上成人的主要死亡原因。
不幸的是,早期诊断和治疗发展的进步受到了匮乏
敏感的生物标志物可以检测早期,功能相关的,神经分子的变化:尽管数据
从基因组广泛的关联研究中揭示了与健康先天免疫功能丧失有关的基因
作为AD的主要危险因素,仍然需要生物标志物研究神经免疫功能
在这种疾病的发展和发展期间。正电子发射断层扫描(PET)是极其的
敏感的分子成像模态非常适合研究此类生物标志物,并建立了非效用
生化过程的体内询问。现有的神经炎症的宠物生物标志物(例如
易位蛋白18 kDa [TSPO],CB2,CSF1R,P2X7)遭受重大缺点,包括较差
中枢神经系统(CNS)中多种细胞类型的阐明功能和/或表达。
在CNS中,腺苷二磷酸受体P2Y12R仅在小胶质细胞上表达
中枢神经系统的免疫效应细胞,并驱动趋化性和与小胶质细胞相关的形态变化
激活。普遍认为是稳态小胶质细胞的生物标志物,P2Y12表达一直是
证明急性(例如脂多糖挑战)和慢性(例如AD)的急性减少
神经炎症。来自高级AD患者的后人类脑组织表现出全球性
降低P2Y12R表达和在周围的小胶质细胞上几乎完全不存在P2Y12R表达
淀粉样蛋白斑块。尽管药理学目标非常出色,但目前仍有
无CNS-PENETION P2Y12R PET示踪剂。为了满足这种未满足的需求,我确定了临床药物的候选者
AZD1283作为可承诺的宠物示踪剂。最近,我设计了一种radiolabel的策略
碳11(T1/2 = 20.4分钟),合成[11C] AZD1283,表明它在人血浆中的体外非常稳定。
在这里,我将[11C] AZD1283与TSPO PET示踪剂[11C] DPA-713进行比较,以测量其测量更改的能力
在两个鼠神经炎症模型中的小胶质细胞中(AIM 1)。此外,我将评估翻译
[11C] AZD1283通过成像健康的非人类灵长类动物和人类体外自显影术的潜力
广告脑组织(AIM 2)。通过追求这些目标获得的经验将使我直接发展技能
适用于未来的独立研究开发针对免疫系统的示踪剂和疗法。我会
在米歇尔·詹姆斯(Michelle James)的心态下进行这项工作
斯坦福大学病理学主席Thomas Montine,医学博士Thomas Montine的额外精神训练。他们的精神训练
与我在斯坦福大学提供的优质培训环境和资源相结合,非常高
导电以成功完成该项目,并最终将成功过渡到职业
作为创新和有效的独立物理科学家。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Isaac Mackenzie Jackson其他文献
Isaac Mackenzie Jackson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Merging artificial intelligence (AI) and pharmacometrics to elucidate gene-drug interactions linked to clopidogrel responsiveness in Caribbean Hispanic patients
融合人工智能 (AI) 和药理学,阐明与加勒比西班牙裔患者氯吡格雷反应相关的基因药物相互作用
- 批准号:
10626448 - 财政年份:2023
- 资助金额:
$ 4.04万 - 项目类别:
CD39-carrying extracellular vesicles regulate pulmonary thrombosis in Sickle Cell Disease
携带CD39的细胞外囊泡调节镰状细胞病中的肺血栓形成
- 批准号:
10736531 - 财政年份:2023
- 资助金额:
$ 4.04万 - 项目类别:
CD38 activation of TRPM2 in hippocampal neurons contributes to stroke-induced cognitive dysfunction
海马神经元中 TRPM2 的 CD38 激活导致中风引起的认知功能障碍
- 批准号:
10536591 - 财政年份:2022
- 资助金额:
$ 4.04万 - 项目类别:
Tuning PARP-1 retention and release on DNA breaks
调节 DNA 断裂时 PARP-1 的保留和释放
- 批准号:
10363534 - 财政年份:2022
- 资助金额:
$ 4.04万 - 项目类别: